Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice

The recent FDA approval of ramucirumab (RAISE trial) has added a third agent to our existing armamentarium of angiogenesis inhibitors (bevacizumab and ziv-aflibercept) for the second-line treatment of metastatic colorectal cancer, which may have some impacts in the current clinic practice.

Detalles Bibliográficos
Autores principales: Goel, Gaurav, Sun, Weijing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517427/
https://www.ncbi.nlm.nih.gov/pubmed/26215324
http://dx.doi.org/10.1186/s13045-015-0183-8
_version_ 1782383188880916480
author Goel, Gaurav
Sun, Weijing
author_facet Goel, Gaurav
Sun, Weijing
author_sort Goel, Gaurav
collection PubMed
description The recent FDA approval of ramucirumab (RAISE trial) has added a third agent to our existing armamentarium of angiogenesis inhibitors (bevacizumab and ziv-aflibercept) for the second-line treatment of metastatic colorectal cancer, which may have some impacts in the current clinic practice.
format Online
Article
Text
id pubmed-4517427
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45174272015-07-29 Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice Goel, Gaurav Sun, Weijing J Hematol Oncol Research Highlight The recent FDA approval of ramucirumab (RAISE trial) has added a third agent to our existing armamentarium of angiogenesis inhibitors (bevacizumab and ziv-aflibercept) for the second-line treatment of metastatic colorectal cancer, which may have some impacts in the current clinic practice. BioMed Central 2015-07-28 /pmc/articles/PMC4517427/ /pubmed/26215324 http://dx.doi.org/10.1186/s13045-015-0183-8 Text en © Goel and Sun. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Highlight
Goel, Gaurav
Sun, Weijing
Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
title Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
title_full Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
title_fullStr Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
title_full_unstemmed Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
title_short Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
title_sort ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
topic Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517427/
https://www.ncbi.nlm.nih.gov/pubmed/26215324
http://dx.doi.org/10.1186/s13045-015-0183-8
work_keys_str_mv AT goelgaurav ramucirumabanotherantiangiogenicagentformetastaticcolorectalcancerinsecondlinesettingitsimpactonclinicalpractice
AT sunweijing ramucirumabanotherantiangiogenicagentformetastaticcolorectalcancerinsecondlinesettingitsimpactonclinicalpractice

Ejemplares similares